Keywords: Multiple sclerosis, Market drivers, Decision Resources, Novaratis, Gilenia, Merck KGaA, Cladribine, Genzyme, Bayer, Alemtuzumab

Eight novel disease-modifying therapies will drive modest growth in the multiple sclerosis drug market through 2019

Article | 13 July 2010

Print This

The launch of several high-priced novel disease-modifying therapies - including the first oral agents approved for the indication - will ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in